BCL2 and B-cell non-Hodgkin lymphoma: Taken together, SC-1 represents a triple-hit B-cell lymphoma cell line, in which IGH rearrangements target FL-specific oncogene BCL2, MYC, as well as a novel target at 17q21, together with fusion of BCL6 and MBNL1.